In Vitro Data Not Relevant To Clinical Use Should Be Cleared From Label - FDA
Executive Summary
Sponsors would have one year to remove in vitro data that has not been clinically validated from labeling, under proposed FDA guidelines for simplified prescription drug labeling.
You may also be interested in...
Antibiotic Labeling Revisions For Changes In Efficacy Suggested By Cmte.
Older antibiotics should be reviewed for potential labeling updates regarding their efficacy against certain pathogens, members of FDA's Anti-Infective Drugs Advisory Committee said July 11
Antibiotic Labeling Revisions For Changes In Efficacy Suggested By Cmte.
Older antibiotics should be reviewed for potential labeling updates regarding their efficacy against certain pathogens, members of FDA's Anti-Infective Drugs Advisory Committee said July 11
PhRMA/FDA Hepatox Group Wants Research On Liver Monitoring
Actelion's pulmonary hypertension agent Tracleer may provide an opportunity for FDA and industry to test new approaches for management of liver toxicity